Introduction
Fibromyalgia presents a clinical enigma. Its pathophysiology is not well understood and its symptoms are nonspecific and overlap with many disorders, making its diagnosis a challenge for clinicians and researchers. Efforts have been made to develop a set of diagnostic criteria for this disorder. Classification criteria were developed in 1990 and diagnostic criteria were implemented in 2010 by the American College of Rheumatology (ACR). The 2010 criteria were modified in 2011 and further modifications to the criteria were introduced in 2016, [1] [2] [3] [4] these are currently the most accepted methods of fibromyalgia diagnosis. These criteria rely heavily on expert clinician opinion and are not definitive diagnostic tests, therefore they produce large heterogeneity within the diagnosed population. Additionally, many physicians are not compliant with the diagnostic criteria and do they do not have a comprehensive understanding of the disorder. [5] [6] [7] [8] They rely on their clinical acumen and judgment for diagnosis, introducing additional variability into the diagnosed population.
The 1990 ACR diagnostic criteria suggest that widespread pain is the main classifying and clinical characteristic of fibromyalgia. 1 The 1990 criteria were revisited in 2010 to account for patients who present less muscle tenderness and more secondary symptoms, in addition to addressing poor physician use of the tender point count. The 2010 criteria introduced a new group of patients who present with higher severity of secondary symptoms such as depression, poor sleep, cognitive symptoms, and somatic symptoms with a minimum of three tender regions. 2, 4 The 2016 revision necessitated a minimum of four tender regions, one in each of four quadrants in the body, with a high symptom severity score (>9) for a diagnosis of fibromyalgia. These changes introduce more heterogeneity into the diagnosis of patients with fibromyalgia as some may present with high affective distress and little muscle pain, and others may present with high levels of muscle pain and little affective and sleep distress. Therefore, a substantial barrier for fibromyalgia diagnosis is the lack of specificity of its diagnostic signs and symptoms. The specific features of the diagnostic criteria for fibromyalgia are themselves common across a wide range of conditions, beyond even immediate differential diagnoses for fibromyalgia. Most patients presenting with one or more of muscle aches and pain, fatigue, poor sleep and mild cognitive symptoms still may not have a formal diagnosis of fibromyalgia. It is also possible that the current fibromyalgia population is composed of patients who may present primarily with depression, a sleep disorder, a cognitive affective disorder or a somatic disorder along with a limited amount of muscle aches and pain. [2] [3] [4] Symptoms such as pain, fatigue, sleep disturbances, cognitive difficulties and depression are nonspecific and can also be caused by different pathophysiological mechanisms.
Current literature shows that the tender point count criterion has been shown to poorly differentiate between fibromyalgia and other pain disorders such as myofascial pain syndrome. 9,10 Gerwin and colleagues 11,12 also report the clinical presence of tender points in 79% of patients with myofascial pain syndrome and an overlap with fibromyalgia of approximately 40%. Additionally, the tender point count is typically higher in women relative to men, therefore more women are likely to be diagnosed with fibromyalgia. 13, 14 Jones and colleagues 15 found that more women were diagnosed with fibromyalgia relative to men using the 1990, 2010 and modified 2010 criteria. However, the prevalence of women with fibromyalgia relative to men using the 1990 criteria, which utilizes only the tender point count, was 13.7 fold and was lower for the other criteria. Several studies have delineated clinical subgroups among patients with fibromyalgia diagnosed with the 1990 criteria, which is considered the most specific definition of fibromyalgia, suggesting that the 1990 criteria diagnose a heterogeneous spectrum of patients. [16] [17] [18] The severity of the variables assessed in the subgroups ranged from experiencing psychological wellbeing, low pain and little disability to displaying physiological (neuroendocrine, immune, metabolic) dysregulation, high anxiety, as well as severe pain and disability. These presentations could theoretically have been the result of various pathophysiological mechanisms. Therefore, the 2010, 2011 and 2016 criteria likely diagnose a more heterogeneous group of individuals relative to the 1990 criteria. [16] [17] [18] Methodological problems associated with the accepted classification and diagnostic criteria There are some methodological problems associated with the creation of the 1990 classification criteria and subsequently the 2010, 2011 and 2016 criteria that may lead to the diagnosis of a heterogeneous group of patients. Figure 1 highlights the factors that are contributing to the diagnostic heterogeneity.
The 1990 classification criteria were developed through consensus from fibromyalgia experts using clinical observations and assessments. 1 Criteria developed through expert consensus increases the chances for misdiagnosis because they are limited to information available to the expert at that time, which may not be comprehensive, and is biased by their internal concept of the disorder which is dependent on their clinical experience. 19 These types of criteria also vary across time and countries, where different representations of the same condition are accepted. 19 Therefore, the sensitivity of 88.4% and specificity of 81.1% reported for the 1990 criteria may not have been accurate. The 2010 criteria were developed using the 1990 criteria as the reference standard. 2 Since the 1990 criteria are not a perfect diagnostic tool, the chance of error when developing the 2010 criteria increased. No statistical adjustments were used to determine accuracy rates reflective of the variability in physician and assessor judgments for both the 1990 and 2010 criteria. The 2011 modification used a different reference standard than the previous criteria, the National Data Bank of Rheumatic Diseases, in which the fibromyalgia population was determined by many different clinicians with undefined diagnostic methods. This further impacts the diagnostic accuracy of these criteria The current challenge facing researchers and clinicians is to identify a diagnostic marker indicative of a causal mechanism associated with fibromyalgia to increase the accuracy of diagnosis. Current research suggests that central sensitization is a primary candidate representative of the pathophysiology underlying fibromyalgia. 25, 26 The current criteria were not constructed to be specific to people with central sensitization but rather individuals with a cluster of symptoms that expert panels of clinicians have defined as fibromyalgia. The criteria likely diagnose a consistent spectrum of patients; however, they may not capture the true presence of fibromyalgia. The specific mechanism responsible for the sensitization associated with fibromyalgia development should be elucidated since central sensitization has multiple etiologies (e.g. bacterial infection, inflammation, etc.). 27, 28 This should allow for the separation of the overall population based upon the underlying mechanism into specific clinical groups each with a unique underlying pathology and a consistent set of symptoms. The following section presents findings on potential pathophysiological indicators of fibromyalgia. Total oxidative status and immune responses are also high in fibromyalgia. 42 The presence of antiserotonin antibodies is more common between fibromyalgia and chronic fatigue syndrome relative to other disorders. 43 Polymorphisms in genes coding for serotonin transporters and catechol-o-methyl transferase are associated with high pain sensitivity in fibromyalgia. These findings suggest there may be a neuroimmune basis to this disorder. A robust effect demonstrated in several studies suggests that levels of interleukin (IL)-6, IL-8 and IL-10 are high in fibromyalgia relative to healthy normal or other pain and central sensitivity disorders. [44] [45] [46] Furthermore, tumor necrosis factor α has been consistently elevated in disorders of central sensitization, including fibromyalgia. 45, [47] [48] [49] Positive correlations exist between these inflammatory markers and clinical symptom severity. Zanette and colleagues 50 identified a strong correlation between increased serum brain-derived neurotrophic factor and S100B protein levels, which is associated with the coexistence of neurological disease and central sensitivity syndrome, with lower pressure pain thresholds in patients with fibromyalgia. Their findings provide a significant initial step towards developing biomarkers diagnostic of fibromyalgia, ultimately to create a well defined group and clinical definition.
Findings on pathophysiological perturbations in fibromyalgia
Advanced brain imaging in fibromyalgia has demonstrated increases in functional connectivity between anatomical cortical regions associated with attention, emotion and somatosensory processing, including the anterior cingulate cortex, anterior prefrontal cortex, parietal cortex, dorsolateral prefrontal cortex and the insula. 51 Increases in functional connectivity between these areas is associated with symptom (pain, depression) severity and pain duration in fibromyalgia. 52 There have also been studies demonstrating attenuated blood flow to brain areas associated with inducing analgesic effects, and increased activity in the primary and secondary somatosensory cortices in people with fibromyalgia. 51 This suggests that their nervous system is compensating for the increase in nociceptive signals received from the spinal cord and is being subject to hypermetabolic states due to large amounts of sustained afferent input. Increases in the glutamate to glutamine ratio are positively associated with the degree of functional connectivity and metabolism in brain areas implicated in central sensitization and fibromyalgia. 53,54 Decreases in dopamine binding and precursor uptake are also associated with the attentional and pain processing abnormalities observed in fibromyalgia. 55, 56 These findings point to a multi axial interaction between neurological, endocrine and immune systems that results in the development of central sensitization in fibromyalgia. We suggest the development of new diagnostic criteria that are based upon clinical and central sensitization attributes that better characterize fibromyalgia. At present, the application of the diagnostic criteria will result in a heterogeneous group that consists of subgroups.
Discussion
Given these findings, researchers should strive towards creating subgroups within patients diagnosed by the current criteria or those with central sensitization, using some of the well researched biomarkers. This should identify distinct underlying pathophysiological mechanisms among the patients and create novel groups, one of which should be fibromyalgia. For example, biomarkers that are common to fibromyalgia and other disorders, such as cortisol, can be used to develop diagnostic cutoffs that help to create better boundaries for each condition and thus improve their distinct definitions. Biomarkers may also be used to understand whether fibromyalgia is truly a singular entity or a psychosomatic manifestation of a spectrum disorder continuous with other psychiatric and pain conditions such as depression, chronic fatigue syndrome or myofascial pain syndrome. A cluster analysis or discriminative function analysis may be used to create a set of criteria that diagnose a homogenous group representing fibromyalgia. Clinical signs and symptoms in combination with indicators of pathophysiological mechanisms known to be associated with fibromyalgia and overlapping disorders should be included. These analyses may inform which variables are highly predictive of overlapping disorders and whether there is a boundary that separates symptomatically overlapping conditions. Following this, the predictive ability of a biomarker profile that can differentiate fibromyalgia from other central sensitization disorders should be undertaken.
Ideally, selected biomarker panels should be able to diagnose fibromyalgia during its earlier phases, during a routine exam or in the presence of questionable symptoms. [57] [58] [59] The biomarker panel profile should indicate the stage or severity of the disorder, be responsive to clinical change and thereby allow for earlier intervention and prevention of progression. Ideally, the biomarker panel should also be responsive to the initiation, continuation, or cessation of external interventions as this will indicate the patient's responsiveness to these interventions. This should address the limitation presented by the 2010 and subsequent criteria, whereby they measure the severity of a patient who already has fibromyalgia symptoms rather than to recognize the presence of the disorder at any of its stages.
In addition to these disease-specific attributes, the ideal biomarker should be acquired easily, noninvasively and affordably for efficient clinical application. Other easily measured and validated clinical features of central sensitization such as the 'pinch and roll' technique, pressure algometry, brush allodynia and weighted pinpricks that provide quantitative measures of pain pressure thresholds and expansion of the receptive fields should be investigated for their utility to diagnosing fibromyalgia. 2, 60, 61 Cold detection threshold as well as dermatographia can also be considered since they reflect the autonomic properties which seem to associated with the manifestation of fibromyalgia. 62,63 Finally, the current clinical criteria should be revisited upon the development of an accurate marker that reflects the pathophysiology underlying fibromyalgia. Validation of the criteria or a subset of the criteria that accurately capture the newly defined fibromyalgia population should be conducted, and they should also be used to augment and indicate the clinical presence of fibromyalgia.
Conclusion
A problem underlying the diagnosis and management of fibromyalgia, extending to other chronic pain disorders, is the symptom-specific rather than a mechanistic approach taken towards its diagnosis and treatment. 64 This method of diagnosis results in the presence of different clinical subgroups presenting different pathophysiological mechanisms under a single pain disorder diagnosis, as is present in fibromyalgia. Many patients may be receiving treatments that may not be suitable for their presenting condition. There is a need for well defined mechanismbased criteria to describe the specific characteristics of fibromyalgia. This should guide the development of more accurate diagnostic methods and effective treatments.
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